Cited by 207Protein Degradation and InhibitorsUbiquitin and proteasome pathwaysChemical Synthesis and Analysis

The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.

Targeted Protein Degradation by Small Molecules

Open access

Bondeson, Daniel P., Crews, Craig M.·2017·Annual Review of Pharmacology and Toxicology

DOI 10.1146/annurev-pharmtox-010715-103507PMC PMC5586045

Open this paper in CoChat — free account Open PDF

Abstract

Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of disease-relevant proteins. Here, we review recent advances in the use of small molecules to degrade proteins in a selective manner. First, we highlight all-small-molecule techniques with direct clinical application. Second, we describe techniques that may find broader acceptance in the biomedical research community that require little or no synthetic chemistry. In addition to serving as innovative research tools, these new approaches to control intracellular protein levels offer the potential to develop novel therapeutics targeting proteins that are not currently pharmaceutically vulnerable.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1146/annurev-pharmtox-010715-103507

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Regulation mechanisms and signaling pathways of autophagy
He, C., & Klionsky, D. J. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102808-114910 · Cited by 3,609
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,888
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citation
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760

Show all 112 references

Research works printed but not linked: 1

Huggins C, 1941, Cancer Res, 168, 293

Sorted by citations

Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
Self-citation
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517
Self-citation
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 523
Self-citation
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 450
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Cromm, P. M., & Crews, C. M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 428
Self-citation
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Han, X., Wang, C., Qin, C., Xiang, W., Fernández‐Salas, E., Yang, C., Wang, M., Zhao, L., Xu, T., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01631 · Cited by 405
SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate
Roy, M. J., Winkler, S., Hughes, S. J., Whitworth, C., Galant, M., Farnaby, W., Rumpel, K., & Ciulli, A. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00092 · Cited by 386
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Donovan, K. A., Ferguson, F. M., Bushman, J. W., Eleuteri, N. A., Bhunia, D., Ryu, S., Tan, L., Shi, K., Yue, H., Liu, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.038 · Cited by 359
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Salami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0105-8 · Cited by 349
Self-citation
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
The PROTAC technology in drug development
Zou, Y., Ma, D., & Wang, Y. (2019) · Cell Biochemistry and Function · doi:10.1002/cbf.3369 · Cited by 312
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
Zeng, M., Xiong, Y., Safaee, N., Nowak, R. P., Donovan, K. A., Yuan, C. J., Nabet, B., Gero, T. W., Feru, F., Li, L., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.12.006 · Cited by 275
Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
Bussiere, D. E., Xie, L., Srinivas, H., Shu, W., Burke, A., Be, C., Zhao, J., Godbole, A., King, D., Karki, R. G., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0411-6 · Cited by 257
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01530 · Cited by 233
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., Xu, T., Wang, M., Yang, C., Chinnaswamy, K., Stuckey, J. A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01393 · Cited by 225
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
Gu, S., Cui, D., Chen, X., Xiong, X., & Zhao, Y. (2018) · BioEssays · doi:10.1002/bies.201700247 · Cited by 231
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Robb, C. M., Contreras, J. I., Kour, S., Taylor, M., Abid, M., Sonawane, Y. A., Zahid, M., Murry, D. J., Natarajan, A., & Rana, S. (2017) · Chemical Communications · doi:10.1039/c7cc03879h · Cited by 223
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras
Zhang, X., Luukkonen, L. M., Eissler, C. L., Crowley, V. M., Yamashita, Y., Schafroth, M. A., Kikuchi, S., Weinstein, D. S., Symons, K. T., Nordin, B. E., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00990 · Cited by 199
Spatiotemporal control of CRISPR/Cas9 gene editing
Zhuo, C., Zhang, J., Lee, J., Jiao, J., Cheng, D., Liu, L., Kim, H., Tao, Y., & Li, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00645-w · Cited by 196
Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function
Luo, M., Spradlin, J. N., Boike, L., Tong, B., Brittain, S. M., McKenna, J. M., Tallarico, J. A., Schirle, M., Maimone, T. J., & Nomura, D. K. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.01.005 · Cited by 186
From Discovery to Bedside: Targeting the Ubiquitin System
Wertz, I. E., & Wang, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.022 · Cited by 162
Bardoxolone conjugation enables targeted protein degradation of BRD4
Tong, B., Luo, M., Xie, Y., Spradlin, J. N., Tallarico, J. A., McKenna, J. M., Schirle, M., Maimone, T. J., & Nomura, D. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72491-9 · Cited by 152
3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation
Testa, A., Lucas, X., Castro, G. V., Chan, K.-H., Wright, J. E., Runcie, A. C., Gadd, M. S., Harrison, W. T. A., Ko, E. J., Fletcher, D., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b05807 · Cited by 143
Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory
Cowan, A. D., & Ciulli, A. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104421 · Cited by 136
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis
Ho, M., Kavanagh, E. L., Dunne, L., Dowling, P., Zhang, L., Lindsay, S., Bazou, D., Goh, C. Y., Hanley, C., Bianchi, G., et al. (2019) · Cancers · doi:10.3390/cancers11010066 · Cited by 132
Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1
Tao, Y., Remillard, D., Vinogradova, E. V., Yokoyama, M., Banchenko, S., Schwefel, D., Melillo, B. N., Schreiber, S. L., Zhang, X., & Cravatt, B. F. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08964 · Cited by 127
Precision Control of CRISPR-Cas9 Using Small Molecules and Light
Gangopadhyay, S. A., Cox, K. J., Manna, D., Lim, D., Maji, B., Zhou, Q., & Choudhary, A. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01202 · Cited by 119
Development of selective mono or dual PROTAC degrader probe of CDK isoforms
Zhou, F., Chen, L., Cao, C.-G., Yu, J., Luo, X., Zhou, P., Zhao, L., Du, W., Cheng, J., Xie, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111952 · Cited by 118
Recent advances in combinatorial drug screening and synergy scoring
Pemovska, T., Bigenzahn, J. W., & Superti‐Furga, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.008 · Cited by 122
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Sincere, N. I., Anand, K., Ashique, S., Yang, J., & You, C. (2023) · Molecules · doi:10.3390/molecules28104014 · Cited by 112
Epigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 111
Targeted Degradation of SLC Transporters Reveals Amenability of Multi-Pass Transmembrane Proteins to Ligand-Induced Proteolysis
Bensimon, A., Pizzagalli, M. D., Kartnig, F., Dvorak, V., Essletzbichler, P., Winter, G. E., & Superti-Furga, G. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.04.003 · Cited by 102
Medicinal chemistry in drug discovery in big pharma: past, present and future
Campbell, I. B., Macdonald, S. J. F., & Procopiou, P. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.007 · Cited by 105
Target protein localization and its impact on PROTAC-mediated degradation
Simpson, L. M., Glennie, L., Brewer, A., Zhao, J., Crooks, J., Shpiro, N., & Sapkota, G. P. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.004 · Cited by 106
Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex
Weerakoon, D., Carbajo, R. J., Maria, L. D., Tyrchan, C., & Zhao, H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01036 · Cited by 95
Exploring the target scope of KEAP1 E3 ligase-based PROTACs
Du, G., Jiang, J., Henning, N. J., Safaee, N., Koide, E., Nowak, R. P., Donovan, K. A., Yoon, H., You, I., Yue, H., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.003 · Cited by 97
Chemo-proteomics exploration of HDAC degradability by small molecule degraders
Xiong, Y., Donovan, K. A., Eleuteri, N. A., Kirmani, N., Yue, H., Razov, A., Krupnick, N. M., Nowak, R. P., & Fischer, E. S. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.07.002 · Cited by 91
RIBOTACs: Small Molecules Target RNA for Degradation
Dey, S. K., & Jaffrey, S. R. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.015 · Cited by 80
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 88
UBE2G1 governs the destruction of cereblon neomorphic substrates
Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S., Surka, C., Mizukoshi, R., Lu, C.-C., Mendy, D., et al. (2018) · eLife · doi:10.7554/elife.40958 · Cited by 78
Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders
Roberts, B. L., Ma, Z., Gao, A., Leisten, E. D., Yin, D., Xu, W., & Tang, W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00140 · Cited by 73
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 69
Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System
Simpson, L. M., Macartney, T., Nardin, A., Fulcher, L. J., Röth, S., Testa, A., Maniaci, C., Ciulli, A., Ganley, I. G., & Sapkota, G. P. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.06.013 · Cited by 71
An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA
Zhao, J., Wang, J., Pang, X., Liu, Z., Li, Q., Yi, D., Zhang, Y., Fang, X., Zhang, T., Zhou, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29690-x · Cited by 65
Discovery of a Potent and Selective Degrader for USP7
Pei, Y., Fu, J., Shi, Y., Zhang, M., Luo, G., Luo, X., Song, N., Mi, T., Yang, Y., Li, J. X., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202204395 · Cited by 68
PIP4Ks Suppress Insulin Signaling through a Catalytic-Independent Mechanism
Wang, D. G., Paddock, M. N., Lundquist, M. R., Sun, J. Y., Mashadova, O., Amadiume, S. C., Bumpus, T. W., Hodakoski, C., Hopkins, B. D., Fine, M. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.070 · Cited by 61
Unveiling the hidden interactome of CRBN molecular glues
Baek, K., Metivier, R. J., Burman, S. S. R., Bushman, J. W., Yoon, H., Lumpkin, R. J., Ryan, J. K., Abeja, D. M., Lakshminarayan, M., Yue, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62099-w · Cited by 77
Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease
Qu, L., Li, S., Ji, L., Luo, S., Ding, M., Yin, F., Wang, C., Luo, H., Lu, D., Liu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113889 · Cited by 61
Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
Jin, J., Wu, Y., Zhao, Z., Wu, Y., Zhou, Y.-D., Liu, S., Sun, Q., Yang, G., Lin, J., Nagle, D. G., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160606 · Cited by 57
“Moreover, the catalytic nature of PROTAC can achieve and maintain enhanced target degradation at low doses (23, 25).”
Drug design targeting active posttranslational modification protein isoforms
Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 56
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 57
Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
Chapdelaine, A. G., & Sun, G. (2023) · Biomolecules · doi:10.3390/biom13081207 · Cited by 58
Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)
Chen, Y. X., Yuan, X., Tang, M., Shi, M., Yang, T., Liu, K., Deng, D., & Chen, L. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105508 · Cited by 51
A HaloTag-Based Multicolor Fluorogenic Sensor Visualizes and Quantifies Proteome Stress in Live Cells Using Solvatochromic and Molecular Rotor-Based Fluorophores
Liu, Y., Miao, K., Li, Y., Fares, M., Chen, S., & Zhang, X. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00135 · Cited by 54
Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches within Tumor Cells: A Future Perspective of Cancer Management
Allemailem, K. S., Almatroodi, S. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Al‐Megrin, W. A. I., Aljamaan, A. N., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087052 · Cited by 53
Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges
Ye, P., Chi, X., Cha, J., Luo, S., Yang, G., Yan, X., & Yang, W. (2021) · Cells · doi:10.3390/cells10123309 · Cited by 51
Biology and Therapy of Dominant Fusion Oncoproteins Involving Transcription Factor and Chromatin Regulators in Sarcomas
Perry, J. A., Seong, B. K. A., & Stegmaier, K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055710 · Cited by 42
1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC
Dokla, E. M. E., Fang, C., Abouzid, K. A. M., & Chen, C. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111607 · Cited by 46
Small-Molecule Approaches to Targeted Protein Degradation
Faust, T. B., Donovan, K. A., Yue, H., Chamberlain, P. P., & Fischer, E. S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051420-114114 · Cited by 45
Precisely controlling endogenous protein dosage in hPSCs and derivatives to model FOXG1 syndrome
Zhu, W., Zhang, B., Li, M., Mo, F., Mi, T., Wu, Y., Teng, Z., Zhou, Q., Li, W., & Hu, B. (2019) · Nature Communications · doi:10.1038/s41467-019-08841-7 · Cited by 46
Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45
Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
Reyes-Garau, D., Ribeiro, M. L., & Roué, G. (2019) · Cancers · doi:10.3390/cancers11101483 · Cited by 45
Targeting protein quality control pathways in breast cancer
Sannino, S., & Brodsky, J. L. (2017) · BMC Biology · doi:10.1186/s12915-017-0449-4 · Cited by 43
“Mallostery”—ligand-dependent protein misfolding enables physiological regulation by ERAD
Wangeline, M. A., & Hampton, R. Y. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001808 · Cited by 41
Basis for metabolite-dependent Cullin-RING ligase deneddylation by the COP9 signalosome
Lin, H., Zhang, X., Liu, L., Fu, Q., Zang, C., Ding, Y., Su, Y., Xu, Z., He, S., Yang, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911998117 · Cited by 38
Small molecules that target the ubiquitin system
Wu, H. Q., Baker, D. A., & Ovaa, H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190535 · Cited by 43
Synthetic Control of Protein Degradation during Cell Proliferation and Developmental Processes
Trauth, J., Scheffer, J., Hasenjäger, S., & Taxis, C. (2019) · ACS Omega · doi:10.1021/acsomega.8b03011 · Cited by 34
A PROTAC targets splicing factor 3B1
Gama-Brambila, R. A., Chen, J., Zhou, J., Tascher, G., Münch, C., & Cheng, X. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.018 · Cited by 37
Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity
Hu, J., Hu, B., Xu, F., Wang, M., Qin, C., McEachern, D., Stuckey, J. A., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00520 · Cited by 36
Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs)
Nalawansha, D. A., Paiva, S.-L., Rafizadeh, D. N., Pettersson, M., Qin, L., & Crews, C. M. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00224 · Cited by 33
Self-citation
Retracted
IP6-assisted CSN-COP1 competition regulates a CRL4-ETV5 proteolytic checkpoint to safeguard glucose-induced insulin secretion
Lin, H., Yan, Y. C., Luo, Y., So, W. Y., Wei, X., Zhang, X., Yang, X., Zhang, J., Su, Y., Yang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22941-3 · Cited by 32
A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment
Chen, G., Kong, Y., Li, Y., Huang, A., Wang, C., Zhou, S., Yang, Z., Wu, Y., Ren, J., & Ying, T. (2021) · Biomolecules · doi:10.3390/biom11101512 · Cited by 32
Recent Updates of the CRISPR/Cas9 Genome Editing System: Novel Approaches to Regulate Its Spatiotemporal Control by Genetic and Physicochemical Strategies
Allemailem, K. S., Almatroudi, A., Rahmani, A. H., Alrumaihi, F., Alradhi, A. E., Al-Subaiyel, A., Algahtani, M., Almousa, R. M., Mahzari, A., Sindi, A. A. A., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455574 · Cited by 36
Engineering Covalent Aptamer Chimeras for Enhanced Autophagic Degradation of Membrane Proteins
Shi, Y., Yun, Y., Wang, R., Liu, Z., Wu, Z., Xiang, Y., & Zhang, J. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202425123 · Cited by 31
Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?
Powell, M., Blaskovich, M. A. T., & Hansford, K. A. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00203 · Cited by 29
PROTAC Technology as a New Tool for Modern Pharmacotherapy
Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., Jamil, A., & Nowaczyk, A. (2025) · Molecules · doi:10.3390/molecules30102123 · Cited by 30
Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues
Marei, H. E. S., Bedair, K., Hasan, A., Al-Mansoori, L., Gaiba, A., Morrione, A., Cenciarelli, C., & Giordano, A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00931-8 · Cited by 31
Into the Fray! A Beginner's Guide to Medicinal Chemistry
Veale, C. G. L. (2021) · ChemMedChem · doi:10.1002/cmdc.202000929 · Cited by 28
Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
Muddassir, M., Soni, K. V., Sangani, C. B., AlArifi, A. S., Afzal, M. F., Abduh, N. A. Y., Duan, Y., & Bhadja, P. (2020) · RSC Advances · doi:10.1039/d0ra07971e · Cited by 27
Structural Basis of Conformational Dynamics in the PROTAC‐Induced Protein Degradation
Zhao, H. (2024) · ChemMedChem · doi:10.1002/cmdc.202400171 · Cited by 25
Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors
Thomas, K. L., Bouguenina, H., Miller, D. S. J., Sialana, F. J., Hayhow, T. G., Choudhary, J. S., Rossanese, O. W., & Bellenie, B. R. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00616 · Cited by 25
Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy–Lysosome Pathway
Cassidy, K. B., & Zhao, H. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00330 · Cited by 25
Proteolysis targeting chimeras in non-small cell lung cancer
Hagopian, G. G., Grant, C., & Nagasaka, M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102561 · Cited by 26
Mapping the substrate landscape of protein phosphatase 2A catalytic subunit PPP2CA
Brewer, A., Sathe, G. J., Pflug, B. E., Clarke, R. G., Macartney, T., & Sapkota, G. P. (2024) · iScience · doi:10.1016/j.isci.2024.109302 · Cited by 23
Recent Advances in Optically Controlled PROTAC
Ouyang, M., Feng, Y. N., Chen, H., Liu, Y., Tan, C., & Tan, Y. C. (2023) · Bioengineering · doi:10.3390/bioengineering10121368 · Cited by 25
Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease
Bhatia, S., Singh, M., Singh, T., & Singh, V. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03722-w · Cited by 22
SPIN4 Is a Principal Endogenous Substrate of the E3 Ubiquitin Ligase DCAF16
Zhang, X., Thielert, M., Li, H., & Cravatt, B. F. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00067 · Cited by 23
Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
Groppe, J. C. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660641 · Cited by 22
Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
Chen, J., Jin, J., Gu, W., Zhao, Z., Hu, Y., Zhou, Y., Nagle, D. G., Xi, Q., Zhang, X., Sun, Q., et al. (2023) · Cancer Science · doi:10.1111/cas.15733 · Cited by 20
Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review
Naufal, M., Hermawati, E., Syah, Y. M., Hidayat, A. T., Hidayat, I. W., & Anshori, J. A. (2024) · ACS Omega · doi:10.1021/acsomega.3c04749 · Cited by 22
Discovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia
Shi, Y., Liu, M., Li, M., Mao, Y., Ma, J., Long, R., Xu, M., Yang, Y., Wang, W., Zhou, Y., et al. (2024) · Chemical Science · doi:10.1039/d3sc06558h · Cited by 21
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 21
Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms
Faryal, B., Abideen, Z. U., Irfan, M., Ahmed, H., Jalilov, F. S., Abduraximova, L., & Ashraf, G. A. (2026) · Biomolecules · doi:10.3390/biom16020325 · Cited by 24
The role of small molecules in cell and gene therapy
Brayshaw, L. L., Martinez-Fleites, C., Athanasopoulos, T., Southgate, T. D., Jespers, L. S., & Herring, C. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00221f · Cited by 21
A Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins
Gama-Brambila, R. A., Chen, J., Dabiri, Y., Tascher, G., Němec, V., Münch, C., Song, G., Knapp, S., & Cheng, X. (2021) · JACS Au · doi:10.1021/jacsau.1c00007 · Cited by 21
Reply to Tran et al.: Dimeric KRAS protein–protein interaction stabilizers
Kessler, D., Gollner, A., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Covini, D., Fischer, S., Gerstberger, T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921236117 · Cited by 20
Glutathione peroxidase 8 expression on cancer cells and cancer‐associated fibroblasts facilitates lung cancer metastasis
Xu, Y., Yuan, L., Jiang, X., Su, M., Huang, M., Chen, Y., Zhang, L., Chen, X., Zhu, H., & Lu, J. (2022) · MedComm · doi:10.1002/mco2.152 · Cited by 18
Cullin-RING Ligase Regulation by the COP9 Signalosome: Structural Mechanisms and New Physiologic Players
Rao, F., Lin, H., & Su, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_4 · Cited by 19

Authors: Bondeson, D. P., & Crews, C. M.
Affiliations: Yale University (US)
Corresponding author: Crews, Craig M.
ORCID: Bondeson, Daniel P.
Crews, Craig M.
Venue: Annual Review of Pharmacology and Toxicology
Publisher: Annual Reviews
Published: 2017-01-06
Volume: 57
Issue: 1
Pages: 107-123
ISSN: 0362-1642 (ISSN-L)
1545-4304
DOI: 10.1146/annurev-pharmtox-010715-103507
PMC: PMC5586045
OpenAlex: W2530302741
Cited by: 207
References: 112
Citations by year: 2026: 25 · 2025: 34 · 2024: 15 · 2023: 17 · 2022: 17 · 2021: 24 · 2020: 22 · 2019: 32 · 2018: 13 · 2017: 7
FWCI: 1.60
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: The Annual Review of Pharmacology and Toxicology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (F99CA212229, R35CA197589)
National Institute of General Medical Sciences (T32GM007223)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: targeted protein degradation, small molecules, proteostasis, selective protein degradation, drug repurposing, therapeutic target, research tools
MeSH terms: Animals, Humans, Oligopeptides, Proteins, Drug Delivery Systems, Small Molecule Libraries, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeted Protein Degradation by Small Molecules

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks